文献速递骨软组织肉瘤与黑色素瘤

伊匹木单抗再诱导用于组合免疫治疗获得性耐药后的晚期黑色素瘤

Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.
PubMed 文献 · Eur J Cancer · 2021-06-29

该回顾性多中心研究纳入47例对纳武利尤单抗联合伊匹木单抗诱导治疗获得完全缓解、部分缓解或持续疾病稳定后进展的晚期黑色素瘤患者,再诱导治疗(伊匹木单抗±抗PD-1)的缓解率为26%,疾病控制率为45%,中位总生存17个月,但58%出现免疫相关不良事件,38%为3/4级。

要点

  • 再诱导治疗缓解率26%,疾病控制率45%,临床活性有限。
  • 58%出现免疫相关不良事件,其中38%为3/4级。
  • 27例中11例(40%)再诱导时重现诱导期相同的免疫相关不良事件。

核心结论

  • 伊匹木单抗±抗PD-1再诱导在组合免疫治疗获得性耐药后具有中等临床活性。
  • 临床医生应警惕免疫相关不良事件风险,包括诱导期发生过的免疫相关不良事件再重现。

研究设计与样本

  • 回顾性多中心分析,从12个中心识别47例晚期黑色素瘤患者。
  • 患者对纳武利尤单抗联合伊匹木单抗诱导治疗后获得完全缓解、部分缓解或持续疾病稳定,随后进展并接受伊匹木单抗(单药或联合抗PD-1)再诱导。

主要发现

  • 再诱导治疗缓解率为12/47(26%),疾病控制率为21/47(45%)。
  • 在停止诱导免疫治疗后出现获得性耐药的患者中缓解似乎更常见(30% vs. 18%,P = 0.655)。
  • 至获得性耐药时间为11个月(95% CI 8-15个月)。
  • 中位随访16个月(95% CI 10-25个月)后,再诱导缓解者的中位无进展生存期为14个月(95% CI 13-NR个月),全队列再诱导后中位总生存为17个月(95% CI 12-NR个月)。
  • 报告27例(58%)免疫相关不良事件,其中18例(38%)为3/4级;27例中11例(40%)再诱导时重现诱导期相同的免疫相关不良事件。

关键数值与推荐

  • 再诱导缓解率26%(12/47),疾病控制率45%(21/47)。
  • 至获得性耐药时间11个月(95% CI 8-15个月)。
  • 再诱导缓解者中位无进展生存14个月(95% CI 13-NR个月),全队列再诱导后中位总生存17个月(95% CI 12-NR个月)。
  • 免疫相关不良事件发生率58%(27/47),3/4级38%(18/47),相同事件重现40%(11/27)。

临床怎么用

  • 对组合免疫治疗获得性耐药的晚期黑色素瘤患者,可考虑伊匹木单抗±抗PD-1再诱导,但需权衡有限的疗效。
  • 再诱导期间应密切监测免疫相关不良事件,尤其关注诱导期曾发生的事件是否重现。

局限性

  • 回顾性研究设计。
  • 样本量较小(47例)。
  • 来自12个中心,可能存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Combination immunotherapy with nivolumab and ipilimumab has a high initial response rate in advanced melanoma; however, up to 55% of patients later progress. The efficacy and safety of ipilimumab re-induction in the setting of acquired resistance (AR) to combination immunotherapy is unknown. METHODS: Patients with advanced melanoma who initially achieved a complete response, partial response or sustained stable disease to induction combination immunotherapy then progressed and were reinduced with ipilimumab (alone or in combination with anti-PD-1) and were analysed retrospectively. Demographics, disease characteristics, efficacy and toxicity were examined. RESULTS: Forty-seven patients were identified from 12 centres. The response rate to reinduction therapy was 12/47 (26%), and disease control rate was 21/47 (45%). Responses appeared more frequent in patients who developed AR after ceasing induction immunotherapy (30% vs. 18%, P = 0.655). Time to AR was 11 months (95% confidence interval [CI], 8-15 months). After a median follow-up of 16 months (95% CI, 10-25 months), responders to reinduction had a median progression-free survival of 14 months (95% CI, 13, NR months), and in the whole cohort, the median overall survival from reinduction was 17 months (95% CI, 12-NR months). Twenty-seven (58%) immune-related adverse events (irAEs) were reported; 18 (38%) were grade 3/4, and in 11 of 27 (40%), the same irAE observed during induction therapy recurred. CONCLUSIONS: Reinduction with ipilimumab ± anti-PD-1 has modest clinical activity. Clinicians should be attentive to the risk of irAEs, including recurrence of irAEs that occurred during induction therapy. Future studies are necessary to determine best management after resistance to combination immunotherapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hepner A, Atkinson VG, Larkin J, et al. Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy. Eur J Cancer. 2021. PMID: 34214936. doi:10.1016/j.ejca.2021.04.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。